Y-mAbs Therapeutics (YMAB) Competitors $8.61 0.00 (0.00%) As of 09/16/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock YMAB vs. VCEL, AVDL, GPCR, SDGR, ABCL, JANX, RCUS, SNDX, ARDX, and STOKShould you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include Vericel (VCEL), Avadel Pharmaceuticals (AVDL), Structure Therapeutics (GPCR), Schrodinger (SDGR), AbCellera Biologics (ABCL), Janux Therapeutics (JANX), Arcus Biosciences (RCUS), Syndax Pharmaceuticals (SNDX), Ardelyx (ARDX), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry. Y-mAbs Therapeutics vs. Its Competitors Vericel Avadel Pharmaceuticals Structure Therapeutics Schrodinger AbCellera Biologics Janux Therapeutics Arcus Biosciences Syndax Pharmaceuticals Ardelyx Stoke Therapeutics Y-mAbs Therapeutics (NASDAQ:YMAB) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability. Which has preferable valuation and earnings, YMAB or VCEL? Vericel has higher revenue and earnings than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioY-mAbs Therapeutics$87.68M4.46-$29.67M-$0.50-17.22Vericel$237.22M6.90$10.36M$0.12270.33 Is YMAB or VCEL more profitable? Vericel has a net margin of 2.85% compared to Y-mAbs Therapeutics' net margin of -26.03%. Vericel's return on equity of 2.47% beat Y-mAbs Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Y-mAbs Therapeutics-26.03% -24.60% -18.89% Vericel 2.85%2.47%1.69% Do insiders and institutionals believe in YMAB or VCEL? 70.9% of Y-mAbs Therapeutics shares are held by institutional investors. 19.7% of Y-mAbs Therapeutics shares are held by insiders. Comparatively, 5.2% of Vericel shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts recommend YMAB or VCEL? Y-mAbs Therapeutics presently has a consensus target price of $9.62, indicating a potential upside of 11.76%. Vericel has a consensus target price of $60.40, indicating a potential upside of 86.19%. Given Vericel's stronger consensus rating and higher probable upside, analysts clearly believe Vericel is more favorable than Y-mAbs Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Y-mAbs Therapeutics 2 Sell rating(s) 8 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80Vericel 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk & volatility, YMAB or VCEL? Y-mAbs Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Vericel has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Does the media prefer YMAB or VCEL? In the previous week, Vericel had 1 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 1 mentions for Vericel and 0 mentions for Y-mAbs Therapeutics. Vericel's average media sentiment score of 1.76 beat Y-mAbs Therapeutics' score of 0.00 indicating that Vericel is being referred to more favorably in the news media. Company Overall Sentiment Y-mAbs Therapeutics Neutral Vericel Very Positive SummaryVericel beats Y-mAbs Therapeutics on 14 of the 16 factors compared between the two stocks. Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding YMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart YMAB vs. The Competition Export to ExcelMetricY-mAbs TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$391.24M$3.36B$6.13B$10.58BDividend YieldN/A2.28%5.67%4.69%P/E Ratio-17.2222.2886.9626.71Price / Sales4.46458.33605.32131.81Price / CashN/A47.8637.9061.31Price / Book4.209.9312.556.55Net Income-$29.67M-$52.80M$3.31B$277.50M7 Day PerformanceN/A5.22%4.28%2.42%1 Month Performance0.35%10.61%6.90%8.63%1 Year Performance-39.19%25.03%70.54%31.60% Y-mAbs Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)YMABY-mAbs Therapeutics1.7589 of 5 stars$8.61flat$9.62+11.8%N/A$391.24M$87.68M-17.22150VCELVericel3.4523 of 5 stars$31.79+5.2%$60.40+90.0%-25.2%$1.53B$237.22M264.94300Positive NewsAVDLAvadel Pharmaceuticals3.1277 of 5 stars$15.31-0.2%$20.86+36.2%+14.7%$1.49B$169.12M-510.3370Positive NewsGPCRStructure Therapeutics3.1298 of 5 stars$25.30+1.2%$68.67+171.4%-36.5%$1.44BN/A-24.10136SDGRSchrodinger3.3834 of 5 stars$20.04+3.8%$27.83+38.9%+17.6%$1.42B$207.54M-8.08790News CoverageAnalyst DowngradeABCLAbCellera Biologics3.2024 of 5 stars$4.87+2.7%$8.00+64.3%+136.0%$1.42B$28.83M-8.85500News CoverageGap UpJANXJanux Therapeutics2.2379 of 5 stars$23.70+2.0%$78.31+230.4%-46.7%$1.40B$439K-13.1730RCUSArcus Biosciences1.628 of 5 stars$13.34+3.9%$21.14+58.5%-19.8%$1.37B$258M-4.21500SNDXSyndax Pharmaceuticals3.6747 of 5 stars$15.56-0.8%$39.22+152.1%-17.1%$1.35B$23.68M-4.00110Analyst RevisionARDXArdelyx4.1088 of 5 stars$5.63+1.6%$11.70+107.8%-22.9%$1.34B$333.61M-24.4890STOKStoke Therapeutics2.6957 of 5 stars$24.73+2.4%$25.57+3.4%+116.8%$1.32B$36.56M29.09100 Related Companies and Tools Related Companies VCEL Competitors AVDL Competitors GPCR Competitors SDGR Competitors ABCL Competitors JANX Competitors RCUS Competitors SNDX Competitors ARDX Competitors STOK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:YMAB) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free YMAB Stock Alerts